Real-World Treatment Patterns and Survival Among Patients with Stage I-III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment.
Soo Jin SeungDaniel MoldaverShazia HassanIqra SyedMaryKate ShanahanGeoffrey LiuPublished in: Oncology and therapy (2024)
In Ontario, between 2010 and 2019, uptake of adjuvant therapy was low among patients with resected NSCLC, despite such therapy being associated with improved survival. Patients assumed to have recurred/relapsed had markedly reduced mOS, regardless of subsequent therapy, compared with those who did not relapse/recur. Novel peri-adjuvant treatment options are needed to enhance outcomes after lung resection.
Keyphrases
- end stage renal disease
- small cell lung cancer
- prognostic factors
- ejection fraction
- acute lymphoblastic leukemia
- chronic kidney disease
- acute myeloid leukemia
- newly diagnosed
- early stage
- stem cells
- lymph node
- high grade
- quantum dots
- peritoneal dialysis
- acute coronary syndrome
- bone marrow
- low grade
- ionic liquid
- atrial fibrillation